Veliparib Facing Phase III Test in BRCA-Positive Breast Cancer

Ariela Katz
Published: Thursday, Jan 12, 2017
Shannon L. Puhalla, MD

Shannon L. Puhalla, MD

Researchers are seeking to determine whether adding the PARP inhibitor veliparib to a chemotherapy combination will improve outcomes for patients with HER2-negative, germline BRCA-associated metastatic or locally advanced breast cancer.

The Brocade 3 trial is being conducted by AbbVie, which is also the company developing the drug. The study is expected to be completed in March 2018.


  1. BRCA1 and BRCA2: cancer risk and genetic testing. National Cancer Institute website. Updated April 1, 2015. Accessed December 30, 2016.
  2. Han HS, DieĢras V, Robson M, et al. Efficacy and tolerability of veliparib (V; ABT-888) in combination with carboplatin (C) and paclitaxel (P) vs placebo (Plc)+C/P in patients (pts) with BRCA1 or BRCA2 mutations and metastatic breast cancer: a randomized, phase 2 study. Presented at: 2016 San Antonio Breast Cancer Symposium; December 6-10, 2016; San Antonio, TX. Abstract S2-05.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: Where Are We Headed in the Treatment of Triple-Negative Breast Cancer?Jul 31, 20191.5
Community Practice Connections™: Evolving Applications for PARP Inhibitors in Ovarian Cancer: Building on a Solid FoundationAug 15, 20191.5
Publication Bottom Border
Border Publication